Mineralocorticoid selectivity: molecular and cellular aspects.
about
Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and AldosteronePseudohyperaldosteronism: pathogenetic mechanismsRole of glucocorticoids in the maturation of the rat renal Na+/H+ antiporter (NHE3)Lack of renal 11 beta-hydroxysteroid dehydrogenase type 2 at birth, a targeted temporal window for neonatal glucocorticoid action in human and mice.Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease.Abnormal regulation of ENaC: syndromes of salt retention and salt wasting by the collecting duct.Mineralocorticoid receptor expression in human venous smooth muscle cells: a potential role for aldosterone signaling in vein graft arterializationRapid non-genomic effects of aldosterone on rodent vascular function.Direct effect of glucocorticoids on glucose-activated adult rat β-cells increases their cell number and their functional mass for transplantation.Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion.Nuclear receptors in neural stem/progenitor cell homeostasis.Effects of aldosterone and related steroids on LPS-induced increased expression of inducible NOS in rat aortic smooth muscle cells.MDM2: a novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling.Glycyrrhetinic acid attenuates vascular smooth muscle vasodilatory function in healthy humans.Increased expression of mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 2 in human atria during atrial fibrillation.Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats.Aldosterone stimulates surface expression of NHE3 in renal proximal brush borders.Design of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) Trial.11β-HSD Types 1 and 2 in the Songbird Brain.11-Beta Dehydrogenase Type 2 Activity Is Not Reduced in Treatment Resistant Hypertension.
P2860
Q26785911-51DA8788-C2FC-418F-B83F-3FC47530AD5BQ28191206-89AF83AC-3182-4BAA-B533-6CD0D369CB2AQ28367625-68536665-A23D-46E8-8BC9-580A75627331Q34168478-732B73C5-1FAC-4CE0-A9DE-8FEC5B4EEE97Q34381424-D1AE0F7E-7143-40B0-8BA9-00B56AC35960Q34731561-5194DC3B-5A24-43A9-856D-EE1207157568Q35087079-28E569A3-3588-40ED-ACBF-6353F9E4E88DQ35850517-8DF7C39B-F869-40B0-BE9B-6040813391F3Q36111049-E3BFD8F7-03E8-4C27-A4EF-CBB804D68C7FQ37003229-1E5F9DC0-364E-4AB1-8556-D6D4550DDF63Q39389805-2A4FAF59-1EAE-4CFA-90D4-80489EA2E665Q40006665-BCC1A9F1-BB08-41B0-9831-E68DFC130A8FQ41089677-8AF153E8-D59E-4CDA-8286-409BAD8C5703Q43048882-FD85F361-B656-4DA0-9FE8-2C49ECF95599Q43197957-FB509D45-FC38-4049-9AD8-3D6DF2F27498Q44279118-FE7FE665-74A9-4CCB-B7CB-36CD3E8A91A0Q44396535-5931BAC7-ADB7-4F7A-96E2-DEE93B54622EQ48363050-D1A41F86-4E0A-4C5B-B05E-B81FA3FB8B6DQ51144125-843A3CAC-FDCA-4F98-B90A-792AF442F9E4Q51144960-F5DBA3B6-74F5-428E-A306-7BD98539D480
P2860
Mineralocorticoid selectivity: molecular and cellular aspects.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Mineralocorticoid selectivity: molecular and cellular aspects.
@ast
Mineralocorticoid selectivity: molecular and cellular aspects.
@en
type
label
Mineralocorticoid selectivity: molecular and cellular aspects.
@ast
Mineralocorticoid selectivity: molecular and cellular aspects.
@en
prefLabel
Mineralocorticoid selectivity: molecular and cellular aspects.
@ast
Mineralocorticoid selectivity: molecular and cellular aspects.
@en
P1433
P1476
Mineralocorticoid selectivity: molecular and cellular aspects.
@en
P2093
P304
P356
10.1046/J.1523-1755.2000.00976.X
P407
P577
2000-04-01T00:00:00Z
P5875
P6179
1031811057